Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

摘要: The aim of this study was to assess the antitumour response and time progression (TTP) patients treated with imatinib mesylate (Glivec®, Gleevec™, formerly STI-571) who had advanced and/or metastatic gastrointestinal stroma tumours (GIST) or other soft tissue sarcomas (STS). Patients measurable lesions adequate organ function were entered. They at dose 400 mg twice daily (bid). All subject a stringent pathological review by an expert panel. Immunohistochemical expression KIT evaluated. A total 51 (27 GIST, 24 STS), median age 53 years, World Health Organization (WHO) performance score 1, 71% received prior chemotherapy. most frequent side-effects anaemia (92%), periorbital oedema (84%), skin rash (69%), fatigue (76%), nausea (57%), granulocytopenia (47%) diarrhoea (47%). Most these mild moderate no patient taken off due side-effects. Skin frequently seem be self limiting, despite continued treatment. In GIST patients, current rates (RRs) are 4% complete remission (CR), 67% partial (PR), 18% stable disease (SD) 11% (PD). 73% free from 1 year. STS group, there objective responses. in subgroup only 58 days. Imatinib is well tolerated bid. This active KIT-positive but subtypes unselected for molecular target unlikely benefit.